Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

112.25
-1.6300-1.43%
Volume:185.93K
Turnover:20.90M
Market Cap:12.13B
PE:247.44
High:114.53
Open:113.26
Low:111.25
Close:113.88
52wk High:126.38
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.59
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:17.19
PE(LYR):136.89

Loading ...

Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?

TIPRANKS
·
Mar 26

Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright

TIPRANKS
·
Mar 26

Corcept Therapeutics rises 28.6%

TIPRANKS
·
Mar 26

What's Behind The Jump In Corcept Therapeutics Stock?

Benzinga
·
Mar 26

US FDA approves Corcept Therapeutics' drug for hard-to-treat ovarian cancer

Reuters
·
Mar 25

Corcept Therapeutics Shares up 46.7% After FDA Approves Co's Drug to Treat Ovarian Cancer

THOMSON REUTERS
·
Mar 25

BRIEF-FDA Approves Relacorilant With NAB-Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube,Primary Peritoneal Cancer

Reuters
·
Mar 25

FDA Approves Relacorilant With Nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

THOMSON REUTERS
·
Mar 25

FDA approves Corcept Therapeutics’ Lifyorli for certain cancers

TIPRANKS
·
Mar 25

Corcept Therapeutics jump 10% after FDA approves Lifyorli cancer treatment

TIPRANKS
·
Mar 25

Corcept Therapeutics trading halted, volatility trading pause

TIPRANKS
·
Mar 25

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:30 AM

Reuters
·
Mar 25

Corcept Chief Development Officer William Guyer disposes of USD 423,000 in common shares

Reuters
·
Mar 25

A Look At Corcept Therapeutics (CORT) Valuation As Shares Trade Below Popular Fair Value Estimates

Simply Wall St.
·
Mar 24

Analysts’ Opinions Are Mixed on These NA Stocks: Corcept Therapeutics (CORT) and Fiserv (FISV)

TIPRANKS
·
Mar 23

Corcept Therapeutics Director G. Leonard Baker Jr acquires USD 3.31 million in common shares

Reuters
·
Mar 20

Corcept faces class action over relacorilant NDA claims after 50.4% stock drop

Reuters
·
Mar 19

Class action lawsuit targets Corcept Therapeutics over alleged securities law violations

Reuters
·
Mar 18

Wolf Haldenstein files securities class action against Corcept Therapeutics over relacorilant statements

Reuters
·
Mar 16

Corcept Therapeutics (CORT) Is Down 5.1% After FDA Relacorilant Rejection And Investor Lawsuits - What's Changed

Simply Wall St.
·
Mar 15